DDInter1544 DDInter22
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Aclidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Aclidinium {u} (Compound) binds {v} (Gene) CHRM2
Aclidinium {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Antagonists
Aclidinium {u} (Compound) causes {v} (Side Effect) Bladder neck obstruction
Aclidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Aclidinium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tiotropium
Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Aclidinium (Compound) binds CHRM2 (Gene)
Aclidinium (Compound) is included by Cholinergic Antagonists (Pharmacologic Class)
Aclidinium (Compound) causes Bladder neck obstruction (Side Effect)
Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Aclidinium (Compound) resembles Tiotropium (Compound) and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium